KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash from Investing Activities (2017 - 2025)

Amneal Pharmaceuticals has reported Cash from Investing Activities over the past 9 years, most recently at -$45.5 million for Q4 2025.

  • Quarterly results put Cash from Investing Activities at -$45.5 million for Q4 2025, down 183.04% from a year ago — trailing twelve months through Dec 2025 was -$112.3 million (down 78.21% YoY), and the annual figure for FY2025 was -$112.3 million, down 78.21%.
  • Cash from Investing Activities for Q4 2025 was -$45.5 million at Amneal Pharmaceuticals, down from -$22.5 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for AMRX hit a ceiling of -$6.5 million in Q2 2024 and a floor of -$97.4 million in Q1 2022.
  • Median Cash from Investing Activities over the past 5 years was -$18.8 million (2024), compared with a mean of -$30.6 million.
  • Peak annual rise in Cash from Investing Activities hit 95.16% in 2021, while the deepest fall reached 828.5% in 2021.
  • Amneal Pharmaceuticals' Cash from Investing Activities stood at -$87.0 million in 2021, then skyrocketed by 86.82% to -$11.5 million in 2022, then plummeted by 176.4% to -$31.7 million in 2023, then skyrocketed by 49.33% to -$16.1 million in 2024, then plummeted by 183.04% to -$45.5 million in 2025.
  • The last three reported values for Cash from Investing Activities were -$45.5 million (Q4 2025), -$22.5 million (Q3 2025), and -$26.5 million (Q2 2025) per Business Quant data.